Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TuHURA Biosciences, Inc./NVDMPI · Entity 6601 | Director | March 30, 2018 | April 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TuHURA Biosciences, Inc./NV
Report date March 30, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,049 |
Reported balance
After 2018-03-30 transaction · row 1
1 source rowRow 1 · 2018-03-30 · Other · Acquired 176 · Balance 64,049 F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2018 Filed Apr 3, 2018 20:01 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-18-003977 · f4033018bacha_delmar.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,049 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,873 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 93,600 | Not disclosed Strike: $4.95 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 7 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,600 Underlying: Common Stock · 93,600 shares Expires 2020-12-31 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | Disposition to issuerOptions (Right to Buy) · Derivative | 93,600 | Not disclosed Strike: $4.95 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 6 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,600 shares Expires 2027-02-17 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 87,500 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 5 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2020-12-31 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | Disposition to issuerOptions (Right to Buy) · Derivative | 87,500 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 4 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2023-08-15 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 3 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2020-12-31 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | Disposition to issuerOptions (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 2 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2022-02-01 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 12:10 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 2,450 | $0.88 | $2,156.00 |
DisclosureSEC source: 0001213900-17-010402 · f4100617bacha_delmarpharm.xml · nonDerivative · entry 2 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,697 Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 12:10 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 7,550 | $0.87 | $6,568.50 |
DisclosureSEC source: 0001213900-17-010402 · f4100617bacha_delmarpharm.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,247 Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:55 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-17-010216 · f4092917bacha_delmarpharm.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,697 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:23 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-17-007139 · f4063017bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,521 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:29 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 6,700 | $3.60 | $24,120.00 |
DisclosureSEC source: 0001213900-17-006878 · f4062617bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,345 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $32,160. Reported price is based on exchange rate of 0.75. Read SEC document |
| June 06, 2017 Filed Jun 6, 2017 21:12 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 5,000 | $2.12 | $10,600.00 |
DisclosureSEC source: 0001213900-17-006196 · f4060617bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,645 Read SEC document |
| May 05, 2017 Filed May 8, 2017 20:58 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 2,500 | $2.20 | $5,500.00 |
DisclosureSEC source: 0001213900-17-004749 · f4050517bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,645 Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:22 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-17-003327 · f4033117bacha_delmar.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,145 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:24 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 93,600 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001213900-17-001711 · f4021717bacha_delmarpharma.xml · derivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,600 Underlying: Common Stock · 93,600 shares Expires 2027-02-17 F1 · derivative.exercise_date: The options vest in equal monthly installments over three years. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 16:44 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 4,000 | $5.00 | $20,000.00 |
DisclosureSEC source: 0001213900-17-000873 · f4020117bacha_delamar.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,969 Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 18:57 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-17-000025 · f4123116bacha_delmar.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,969 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 18:14 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-16-017306 · f4100316bacha_delmar.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,793 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.